Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapies.
Yakugaku Zasshi
; 130(10): 1347-52, 2010 Oct.
Article
in En
| MEDLINE
| ID: mdl-20930487
ABSTRACT
As it is an urgent issue to contain increasing healthcare expenditures, unlimited reimbursement of pharmaceuticals continues to be controversial. The objective of this study is to identify acceptable incremental cost effectiveness ratios between new and conventional therapies. Clinical study data for five statin therapies were used to indicate treatment effectiveness and incremental costs were indicated by price premiums at price listing. The incremental cost effectiveness ratios to pravastatin were 0 yen/patient with response, 1,475.1 yen/patient with response, 3,033.3 yen/patient with response, and 3,032.4 yen/patient with response. By conducting further analyses in various pharmaceuticals and categorizing acceptable incremental cost effectiveness ratios based on the disease severity and expected level of improvement in disease condition, drug prices that reflect the value of new pharmaceuticals and that are reasonable to be reimbursed can be suggested.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pravastatin
/
Cost-Benefit Analysis
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Drug Utilization
/
Insurance, Health, Reimbursement
/
Insurance, Pharmaceutical Services
Type of study:
Health_economic_evaluation
Limits:
Humans
Language:
En
Journal:
Yakugaku Zasshi
Year:
2010
Document type:
Article
Affiliation country:
Japan